Fastest
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →https://www.patsnap.com/resources/blog/rd-blog/electrochemical-biosensor-signal-conditioning-patent-landscape-patent-landscape/ · Patsnap · data cut-off 2026-08-31 · downloaded from the live page
Patent Landscape · Sensors, MEMS, Metrology & InstrumentationElectrochemical Biosensor Signal Conditioning Patents
A data-driven view of electrochemical biosensor signal conditioning patents: filing trends, IPC composition, top assignees, most-cited records and where claim white space remains through 2026.
110
Published Records
30%
Top-5 Share of All Records
+433%
Filing Growth 2021→2024
CN
Leading Jurisdiction
Filing growth = 2021 (3 records) → 2024 (16); 2024 is the last year we treat as complete. Top-5 share = the 5 largest assignees ÷ all 110 records in scope (CR5), not the ranked leaders only.
Published byPatsnap Research··6 min readSourced from Patsnap Eureka
Overview
What this landscape covers
This landscape tracks 110 published records at the intersection of electrochemical biosensor design and signal conditioning — analog front ends, readout circuits and amplification or filtering stages built around G01N material analysis together with H03F and G01D circuitry classes. The scope spans 2015 through the August 2026 cut-off, capturing both the strip-and-meter architectures that dominate glucose and point-of-care testing and the newer signal-amplification techniques aimed at ultra-low-level analyte detection.
Because publication trails filing by roughly 18 months, the 2025 and 2026 counts in the trend data are still filling in and should not be read as a slowdown. The dataset is best read as a snapshot of where claim space is already dense — strip readout and amplification circuitry — versus where genetic and informatics-adjacent classes remain comparatively open.
Filing activity and technology composition, 2015–2026
Source: Patsnap Eureka. Assignee ranking and totals. Derived from a Patsnap search on Electrochemical Biosensor Signal Conditioning Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
10,000 free credits to start
The Numbers
Filing trend and technology composition
Two views of the same 110 records: how filing activity has moved year over year, and which IPC subclasses carry the claim volume. Because a single record can carry several IPC codes, the composition shares add up to more than 100% of records.
A late but sharp acceleration
Annual filings sat in the low single digits from 2017 through the early 2020s before climbing to a peak of 16 records in 2024 — the fastest three-year run in the dataset (2021's 3 records to 2024's 16, +433%). Treat 2025 and 2026 figures as incomplete rather than declining, given normal publication lag.
Publication lags filing by roughly 18 months, so 2025 onwards are still filling in. Growth rates on this page therefore end at 2024; running them to the last bar would understate the field.
G01N dominates; C12Q and C12M carry the bioassay side
Every record in scope sits in G01N (material analysis and testing), which is the anchor class for the search itself. Beneath that, C12Q (enzyme and DNA-based measuring/testing) appears in 36.4% of records and C12M (bioreactors and enzyme apparatus) in 18.2%, showing that a large share of signal-conditioning innovation here is tied directly to bioassay chemistry rather than generic circuit design. Combinatorial chemistry (C40B, 10.9%) and healthcare informatics (G16H, 4.5%) are present but thin.
Shares are the percentage of the 110 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Source: Patsnap Eureka. Filing trend and technology composition. Derived from a Patsnap search on Electrochemical Biosensor Signal Conditioning Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish.
Go deeper on Electrochemical Biosensor Signal Conditioning Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about electrochemical biosensor signal conditioning patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaKey Patents
Representative filing and most-cited prior art
Representative Record
Ultra-sensitive detection of extremely low level biological analytes using electrochemical signal amplification and biosensor (CA2921388C, Gordon Neil, 2016-10-04)
GORDON, NEIL
This invention allows ultra-low levels of virtually any biological analyte to be detected and quantified rapidly, simply and inexpensively with an electrochemical biosensor using a novel electrochemical signal amplification technique. The invention amplifies detection signals from low level analytes using an innovative sandwich ELISA structure that replaces optical labels with a massive amount of electrochemically detectable guanine-rich oligonucleotide tags. Selective binding is achieved with matched pairs of either commercial or custom analyte-binding materials such as monoclonal antibodies or single-strand DNA. The guanine tags are eluted from the sandwich structures and hybridised for detection.Abstract text as filed; lightly formatted for readability.
View full recordMost-cited records in this landscape
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2001071329A1 | Electrochemical biosensor readout meter | 36 |
| 2 | CN102004126A | 电化学生物传感器及其检测方法 | 26 |
| 3 | US20150141272A1 | Ultra-sensitive detection of extremely low level biological analytes using electrochemical signal amplificati… | 25 |
| 4 | CN104237352A | 基于氧化石墨烯、金纳米管和锁核酸探针修饰的电极及其制备方法和应用 | 21 |
| 5 | WO2005003774A1 | Electrochemicalbiosensor test strip and reagent for analyzing physiologicsl sample including blood corpuscles | 18 |
| 6 | CN109655450A | 基于CdTe量子点聚集与循环酶双重放大信号的电化学发光生物传感器的构建及其应用 | 14 |
| 7 | CN110501411A | 一种无酶检测氨苄青霉素的电化学生物传感器及其制备方法和应用 | 13 |
| 8 | US20190079084A1 | Bioanalyte signal amplification and detection with artificial intelligence diagnosis | 12 |
| 9 | CN106568820A | 基于DNA信号放大技术合成银纳米簇的电化学生物传感器的制备方法及其应用 | 12 |
| 10 | CN108845020A | 一种检测氨苄青霉素的电化学生物传感器及其制备方法 | 11 |
Citation counts reflect influence within the searched corpus and skew toward older filings; they are not a measure of current commercial importance.
Patent titles are shown in the language they were filed in, not translated, so that each record stays verifiable against the original filing — a translated title will not match in Eureka or in any national register. Each row carries its publication number; clicking a row searches Eureka by that number.
Source: Patsnap Eureka. Citation counts and representative records. Derived from a Patsnap search on Electrochemical Biosensor Signal Conditioning Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Run it yourself
Put your own technology through the same analysis
Where to run it
For builders
MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Insights
What the data means for filing strategy
Four read-outs from the ranking, trend and citation data that matter more than the raw counts on their own.
Concentration
44.5%
held by top 10 of 110 records
The top 10 hold less than half the field
The leading assignee accounts for 15 of 110 records, and the top 5 combined reach 30.0% of all records in scope. That leaves more than half the field to a long tail of assignees with only a handful of filings each — a structure that still rewards a well-drafted first claim rather than one where the door has already closed.
Based on the 77-company ranking returned for this scope.
Momentum
+433%
2021 to 2024 filing growth
Growth is real, and recent
Filings moved from 3 records in 2021 to 16 in 2024, the fastest run in the dataset's history. That timing lines up with wider interest in ultra-low-level analyte detection and point-of-care diagnostics, not with any single dominant filer.
2025–2026 counts remain incomplete due to normal publication lag.
Geography
60 of 110
records via China receiving office
China leads filing venue by a wide margin
China's receiving office accounts for 60 records, more than five times the United States count of 11 and well ahead of EPO (9), South Korea (8), Canada (7) and WIPO/PCT (7) combined. Competitive monitoring and freedom-to-operate work in this space should start with Chinese-language prior art.
Receiving office counts as filed in the dataset.
Technology mix
36.4%
of records also carry C12Q
Signal conditioning here is bioassay-bound
Beyond the universal G01N anchor, more than a third of records also sit in C12Q (enzyme/DNA measuring and testing), and nearly a fifth in C12M (bioreactors and enzyme apparatus). Circuit-only signal conditioning claims are comparatively rare; most inventions couple the electronics to a specific assay chemistry.
Class shares are computed against all 110 records and overlap by design.
Eureka AI Agent
Looking for what nobody has claimed yet?
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to electrochemical biosensor signal conditioning patent landscape, with the prior art for and against each one.
Where filers are pairing up
| Assignee | Co-assignee | Shared families |
|---|---|---|
| All Medicus Co., Ltd. | RYU JUN OH | 1 |
| All Medicus Co., Ltd. | PARK MI SUK | 1 |
| All Medicus Co., Ltd. | LEE JIN WOO | 1 |
| All Medicus Co., Ltd. | KIM IM OK | 1 |
| All Medicus Co., Ltd. | KANG SEUNG JOO | 1 |
| All Medicus Co., Ltd. | CHOI & HWAN | 1 |
| All Medicus Co., Ltd. | AHN YON CHAN | 1 |
Co-assignment is limited: 7 co-assignee pairs appear across the dataset, the strongest involving a South Korea-based diagnostics firm working with named individual inventors — evidence of small, informal collaboration rather than large joint-venture filing.
Source: Patsnap Eureka. Co-assignee relationships and derived observations. Derived from a Patsnap search on Electrochemical Biosensor Signal Conditioning Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
What's Next
Turning this landscape into a filing decision
The numbers above describe where the field stands; the next step is testing a specific claim idea or a specific competitor against it.
Stress-test a claim direction
Run a candidate independent claim for a new signal-conditioning or amplification approach against the dense G01N/C12Q prior art to see what is already occupied before drafting.
Explore in Patsnap EurekaTrack a specific assignee
Follow the filing cadence of a named leader or a fast-moving new entrant into 2025–2026 as those records continue to publish.
Explore in Patsnap EurekaMap the white space branches
Use the IPC composition to identify which adjacent classes — informatics, microorganism engineering — carry the fewest claims relative to the core.
Explore in Patsnap EurekaSource: Patsnap Eureka. Forward-looking reading of the same dataset. Derived from a Patsnap search on Electrochemical Biosensor Signal Conditioning Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
FAQ
Common questions about this landscape
This landscape tracks 110 published records covering electrochemical biosensor signal conditioning between 2015 and the August 2026 data cut-off. The scope includes analog front ends, readout circuits and amplification or filtering stages classified under G01N together with H03F and G01D. Because publication lags filing by roughly 18 months, the true count for 2025 and 2026 filings will continue to rise as more records publish.
The ranking covers 77 companies and individuals, with the leader holding 15 of the 110 records in scope. The top 5 assignees combined account for 30.0% of all records, and the top 10 combined reach 44.5% — a moderate concentration that still leaves most of the field to lower-volume filers. No single assignee holds a dominant blocking position across the whole space.
Annual filings grew from 3 records in 2021 to a peak of 16 in 2024, a 433% increase over three years. That acceleration lines up with broader industry interest in ultra-sensitive electrochemical detection and point-of-care diagnostics rather than a single company's filing surge. Figures for 2025 and 2026 are not yet complete because of normal publication lag, so the recent trend line should not be read as slowing.
China's receiving office accounts for 60 of the 110 records in this landscape, well ahead of the United States (11), EPO (9), South Korea (8), Canada (7) and WIPO/PCT (7). Any clearance or freedom-to-operate work in this field should start with Chinese-language prior art given that volume, then extend to the other jurisdictions in proportion to their counts.
CA2921388C, filed by Gordon Neil, claims an electrochemical signal amplification technique that replaces optical labels with guanine-rich oligonucleotide tags in a sandwich ELISA structure, enabling detection of ultra-low-level biological analytes. It is one of the more heavily cited records in this dataset and represents a specific amplification chemistry rather than signal-conditioning circuitry generically, which narrows — but does not eliminate — the room for alternative amplification or readout architectures. A design-around assessment should focus specifically on the tagging and hybridisation steps it describes.
Answers are grounded in the same dataset. Derived from a Patsnap search on Electrochemical Biosensor Signal Conditioning Patent Landscape covering 2015–2026, data cut-off 2026-08-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Research Electrochemical Biosensor Signal Conditioning Patent Landscape in depth with Eureka
Go past this page: query the whole electrochemical biosensor signal conditioning patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.